TMO

Thermo Fisher Scientific
D

TMO

Arincen67/100B
706.32
USD
7.96
(1.14%)
Post Trading·709.98USD+3.66(+0.52%)
Last updated: · Delayed 15 min
Fair value599.09Plus+18%433Price 706.32754
Q4 FY2026 · Earnings report
EPS estimate 7.13Revenue estimate 12.84B
OverviewFinancialsForecastEarningsDividendsCompany

Thermo Fisher Scientific net income 1985–2026

Thermo Fisher Scientific earned 1.72B USD in Q3 FY2026, the three months to 26 September 2026, up 6.5% on the same quarter a year before. Thermo Fisher Scientific's net income over the last twelve months was 7.08B USD, up 7.8% on the twelve months before. In fiscal year 2025 it earned 6.74B USD, up 6.3% on the year before.

Last updated 3 Nov 2026 · Next report 4 Feb 2027

Net income

Net income · +13.1% a year over 10 yearsNet margin

Growth

Fiscal yearPeriod endingNet incomeGrowthNet marginRevenue
TTM26 Sept 20267.08B+7.81%14.96%47.35B
FY202531 Dec 20256.74B+6.35%15.12%44.56B
FY202431 Dec 20246.34B+5.67%14.77%42.88B
FY202331 Dec 20236.00B-13.74%13.99%42.86B
FY202231 Dec 20226.95B-10.03%15.47%44.92B
FY202131 Dec 20217.73B+21.18%19.70%39.21B
FY202031 Dec 20206.38B+72.48%19.79%32.22B
FY201931 Dec 20193.70B+25.80%14.47%25.54B
FY201831 Dec 20182.94B+32.04%12.06%24.36B
FY201731 Dec 20172.23B+10.05%10.64%20.92B
FY201631 Dec 20162.02B+2.35%11.06%18.27B
FY201531 Dec 20151.98B+4.28%11.64%16.97B
FY201431 Dec 20141.89B+48.78%11.22%16.89B
FY201331 Dec 20131.27B+8.10%9.73%13.09B
FY201231 Dec 20121.18B-11.43%9.42%12.51B
FY201131 Dec 20111.33B+28.42%11.34%11.73B
FY201031 Dec 20101.04B+21.79%9.60%10.79B
FY200931 Dec 2009850.30M-14.47%8.41%10.11B
FY200831 Dec 2008994.20M+30.63%9.47%10.50B
FY200731 Dec 2007761.10M+350.53%7.81%9.75B
FY200631 Dec 2006168.94M-24.32%4.46%3.79B
FY200531 Dec 2005223.22M-38.31%8.48%2.63B
FY200431 Dec 2004361.84M+80.91%16.40%2.21B
FY200331 Dec 2003200.01M-35.42%9.54%2.10B
FY200231 Dec 2002309.73M—14.85%2.09B
FY200131 Dec 2001-781.00K—-0.04%2.19B
FY200031 Dec 2000-36.11M—-1.58%2.28B
FY199931 Dec 1999-174.60M-195.99%-7.07%2.47B
FY199831 Dec 1998181.90M-23.99%4.70%3.87B
FY199731 Dec 1997239.30M+25.42%6.73%3.56B
FY199631 Dec 1996190.80M+36.19%6.51%2.93B
FY199531 Dec 1995140.10M+35.49%6.35%2.21B
FY199431 Dec 1994103.40M+34.99%6.52%1.59B
FY199331 Dec 199376.60M+29.39%6.13%1.25B
FY199231 Dec 199259.20M+25.69%6.24%949.00M
FY199131 Dec 199147.10M+38.94%5.85%805.50M
FY199031 Dec 199033.90M+37.80%4.79%708.00M
FY198931 Dec 198924.60M+22.39%4.25%579.00M
FY198831 Dec 198820.10M+11.05%4.02%500.60M
FY198731 Dec 198718.10M+26.57%4.72%383.40M
FY198631 Dec 198614.30M+48.96%4.31%331.60M
FY198531 Dec 19859.60M—3.61%265.70M

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

See also:Revenue,EPS,Shares outstanding,Operating income,Cash on hand,Total debt,Free cash flow,Stock buybacks,Income statement

Common questions about Thermo Fisher Scientific's profit

Source: Financial Modeling Prep

Smarter Decisions,Together
FacebookTwitterYoutubeInstagramLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.